SAGE - Sage Therapeutics Inc
IEX Last Trade
8.435
0.345 4.090%
Share volume: 531,209
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$8.09
0.35
4.27%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-08 | 2023-02-16 | 2023-05-02 | 2023-08-07 | 2023-11-07 | 2024-02-14 | 2024-04-25 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 1.486 B | 1.356 B | 1.221 B | 1.082 B | 949.663 M | 882.277 M | 767.600 M | 697.105 M | |
| Current Assets | 1.465 B | 1.337 B | 1.203 B | 1.064 B | 933.270 M | 869.350 M | 755.442 M | 686.811 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 53.017 M | 50.826 M | 58.850 M | 46.321 M | 34.705 M | 31.825 M | 26.588 M | 28.743 M | |
| Short Term Investments | 53.017 M | 50.826 M | 58.850 M | 46.321 M | 34.705 M | 31.825 M | 26.588 M | 28.743 M | |
| Total Receivables | 18.448 M | 13.660 M | 15.002 M | 15.090 M | 22.513 M | 83.009 M | 10.509 M | 9.943 M | |
| Current Cash | 1.394 B | 1.272 B | 1.130 B | 1.003 B | 876.052 M | 753.184 M | 717.013 M | 646.793 M | |
| Total Non-current Assets | 20.969 M | 19.469 M | 17.249 M | 18.261 M | 16.393 M | 12.927 M | 12.158 M | 10.294 M | |
| Property Plant Equipment | 2.821 M | 2.898 M | 2.663 M | 2.480 M | 2.442 M | 1.921 M | 1.585 M | 1.274 M | |
| Other Assets | 4.909 M | 4.770 M | 4.255 M | 6.889 M | 6.593 M | 6.548 M | 6.216 M | 7.800 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.486 B | 1.356 B | 1.221 B | 1.082 B | 949.663 M | 882.277 M | 767.600 M | 697.105 M | |
| Total liabilities | 105.951 M | 103.850 M | 87.557 M | 97.912 M | 133.004 M | 82.747 M | 61.799 M | 69.043 M | |
| Total current liabilities | 99.687 M | 99.259 M | 84.692 M | 96.807 M | 133.004 M | 82.747 M | 61.799 M | 69.043 M | |
| Accounts Payable | 7.077 M | 18.950 M | 12.263 M | 9.283 M | 11.136 M | 10.318 M | 6.479 M | 8.650 M | |
| Other liabilities | 100.000 K | 100.000 K | 102.000 K | 102.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 100.000 K | 100.000 K | 102.000 K | 102.000 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.380 B | 1.253 B | 1.133 B | 984.376 M | 816.659 M | 799.530 M | 705.801 M | 628.062 M | |
| Common stock | 59.428 M | 59.501 M | 59.674 M | 59.770 M | 59.912 M | 59.990 M | 60.136 M | 60.538 M | |
| Retained earnings | -1.881 B | -2.028 B | -2.175 B | -2.335 B | -2.537 B | -2.570 B | -2.678 B | -2.781 B |